Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine-Induced Myelosuppression in Australia: A Budget Impact Analysis.

ABSTRACT: Testing thiopurine methyltransferase (TPMT) enzyme activity or genotype prior to thiopurine prescribing is recommended to reduce the risk of moderate to severe-and potentially fatal-myelosuppression in poor or intermediate TPMT metabolizers. Despite this, only about one-third of individuals prescribed thiopurines in Australia currently receive TPMT testing. The budgetary implications of expanding testing to align with guidelines remain unclear. We conducted a budget impact analysis from the Australian healthcare system perspective, comparing costs under current versus increased TPMT testing uptake. Phenotype frequencies among thiopurine users were estimated using ancestry-stratified prescribing data from the Person Level Integrated Data Asset of the Australian Bureau of Statistics combined

SUBMITTER: Ianni BD 

PROVIDER: S-EPMC12856697 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature